1. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
- Author
-
Cingolani, A., Tummolo, A. M., Montemurro, G., Gremese, E., Larosa, L., Cipriani, M. C., Pasciuto, G., Liperoti, R., Murri, R., Pirronti, T., Cauda, R., Fantoni, M., for COVID 2 Columbus Working Group, Bellieni, A., Brandi, V., Calabrese, A., Calvello, M. R., Ciccullo, A., Corbo, G., and Falsiroli, C.
- Subjects
CHLOROQUINE ,HETEROCYCLIC compounds ,IMMUNOTHERAPY ,INTERLEUKINS ,MONOCLONAL antibodies ,NEUROTRANSMITTER uptake inhibitors ,RESPIRATORY insufficiency ,ANTIRETROVIRAL agents ,JANUS kinases ,COVID-19 - Abstract
A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF